Cartesian Therapeutics Announced Topline Results From Its Phase 2B Trial Of Descartes-08 In Patients With Generalized Myasthenia Gravis, Trial Met The Primary Endpoint With Statistical Significance
$RNAC
Biotechnology: Pharmaceutical Preparations
Health Care
- Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo.
- Deep and durable responses up to at least six months observed in patients treated with Descartes-08.
- Safety profile continues to support outpatient administration.
- Company expects to hold End-of-Phase 2 meeting with the FDA by year-end.